News | February 08, 2022
Merck KGaA restructures life science business to support long-term growth
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
The study will be published on the pre-print server, medRXiv, shortly
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Subscribe To Our Newsletter & Stay Updated
